var data={"title":"Management of mushroom poisoning","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Management of mushroom poisoning</div><dl id=\"topicContributors\"><dt><span> </span>Author:</dt><dd><a href=\"https://www.uptodate.com/contents/management-of-mushroom-poisoning/contributors\" class=\"contributor contributor_credentials\">Timothy J Wiegand, MD, DABAM, FACMT, FAACT</a></dd><dt><span> </span>Section Editors:</dt><dd><a href=\"https://www.uptodate.com/contents/management-of-mushroom-poisoning/contributors\" class=\"contributor contributor_credentials\">Michele M Burns, MD, MPH</a></dd><dd><a href=\"https://www.uptodate.com/contents/management-of-mushroom-poisoning/contributors\" class=\"contributor contributor_credentials\">Stephen J Traub, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/management-of-mushroom-poisoning/contributors\" class=\"contributor contributor_credentials\">James F Wiley, II, MD, MPH</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/management-of-mushroom-poisoning/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Dec 14, 2016.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H10900927\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Ingestion of potentially poisonous mushrooms occurs frequently, but serious toxicity is uncommon. There are 12 groups of identified mushroom toxins with 14 described clinical syndromes (<a href=\"image.htm?imageKey=EM%2F77875\" class=\"graphic graphic_table graphicRef77875 \">table 1</a>). Defining which clinical syndrome predominates, initiating general supportive care, and administering any specific treatments for that syndrome are the key steps in the initial management for mushroom ingestion [<a href=\"https://www.uptodate.com/contents/management-of-mushroom-poisoning/abstract/1,2\" class=\"abstract_t\">1,2</a>]. </p><p>The general management of mushroom poisoning is reviewed here. The clinical manifestations and diagnosis of mushroom poisoning, and the diagnosis and treatment of poisoning caused by mushrooms containing potentially lethal cyclopeptide toxins (eg, amatoxin) and by <em>Amanita smithiana</em> are discussed in greater detail separately. (See <a href=\"topic.htm?path=clinical-manifestations-and-evaluation-of-mushroom-poisoning\" class=\"medical medical_review\">&quot;Clinical manifestations and evaluation of mushroom poisoning&quot;</a> and <a href=\"topic.htm?path=amanita-smithiana-mushroom-poisoning\" class=\"medical medical_review\">&quot;Amanita smithiana mushroom poisoning&quot;</a> and <a href=\"topic.htm?path=amatoxin-containing-mushroom-poisoning-eg-amanita-phalloides-clinical-manifestations-diagnosis-and-treatment\" class=\"medical medical_review\">&quot;Amatoxin-containing mushroom poisoning (eg, Amanita phalloides): Clinical manifestations, diagnosis, and treatment&quot;</a>.) </p><p class=\"headingAnchor\" id=\"H25646897\"><span class=\"h1\">AMATOXIN-CONTAINING MUSHROOM POISONING</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Management of amatoxin-containing mushroom poisoning is covered in greater detail separately. (See <a href=\"#H5135071\" class=\"local\">'General management'</a> below.) </p><p class=\"headingAnchor\" id=\"H5135071\"><span class=\"h1\">GENERAL MANAGEMENT</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>A regional poison control center should be contacted to discuss likely mushroom species ingested based upon clinical findings, identification of any mushrooms available for analysis, and treatment of specific toxic effects. Most poison control centers maintain active call lists of mycologists who are knowledgeable concerning local prevalence of mushroom genera and species and can assist in mushroom identification. To obtain emergent consultation with a medical toxicologist, call the United States Poison Control Network at 1-800-222-1222, or access the World Health Organization's list of international poison centers (<a href=\"http://www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html&amp;token=vYXClxsD0hnrf4M8kYcoD1kMICrGjKQRRaFc8pA0pw9qlhpVmsmYh2e3Gi7webw9H9uSzH3nipQ0rPpTLYBWhGP+/wpQqUegRzvggwgKA6s=&amp;TOPIC_ID=13894\" target=\"_blank\" class=\"external\">www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html</a>).</p><p>Supportive care and gastrointestinal decontamination with activated charcoal suffice for proper management of most patients with mushroom poisoning [<a href=\"https://www.uptodate.com/contents/management-of-mushroom-poisoning/abstract/3\" class=\"abstract_t\">3</a>]. </p><p>Patients who ingest potentially lethal mushrooms (eg, <em>Amanita virosa</em>, <em>Amanita phalloides</em>, <em>Cortinarius orellanus</em>, <em>Gyromitra esculenta</em>) typically develop signs of toxicity more than six hours after ingestion [<a href=\"https://www.uptodate.com/contents/management-of-mushroom-poisoning/abstract/1,4\" class=\"abstract_t\">1,4</a>]. However, clinical manifestations of poisoning that occur less than six hours after ingestion do not exclude the potential for life-threatening toxicity, especially when more than one type of mushroom has been eaten. When specific therapy is necessary, it is guided by clinical presentation and when available, specific mushroom identification (<a href=\"image.htm?imageKey=EM%2F77875\" class=\"graphic graphic_table graphicRef77875 \">table 1</a>). (See <a href=\"topic.htm?path=clinical-manifestations-and-evaluation-of-mushroom-poisoning#H21619983\" class=\"medical medical_review\">&quot;Clinical manifestations and evaluation of mushroom poisoning&quot;, section on 'Mushroom poisoning syndromes'</a> and <a href=\"topic.htm?path=clinical-manifestations-and-evaluation-of-mushroom-poisoning#H21617164\" class=\"medical medical_review\">&quot;Clinical manifestations and evaluation of mushroom poisoning&quot;, section on 'Mushroom identification'</a>.) </p><p class=\"headingAnchor\" id=\"H20098225\"><span class=\"h2\">Supportive care</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Recommendations for care of children and adults with mushroom poisoning are primarily derived from case series and reports and are driven by physical findings. After initial assessment and support of airway, breathing, and circulation as needed, the clinician should anticipate and aggressively manage fluid losses caused by vomiting and diarrhea, which are common findings after toxic mushroom ingestion. The clinician should also be ready to treat symptoms caused by any of the toxic mushrooms (<a href=\"image.htm?imageKey=EM%2F77875\" class=\"graphic graphic_table graphicRef77875 \">table 1</a>). (See <a href=\"topic.htm?path=clinical-manifestations-and-evaluation-of-mushroom-poisoning#H21619983\" class=\"medical medical_review\">&quot;Clinical manifestations and evaluation of mushroom poisoning&quot;, section on 'Mushroom poisoning syndromes'</a>.)</p><p class=\"headingAnchor\" id=\"H1129419\"><span class=\"h3\">Vomiting and diarrhea</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Vomiting and diarrhea may be caused by any of the toxic mushrooms [<a href=\"https://www.uptodate.com/contents/management-of-mushroom-poisoning/abstract/1,3-5\" class=\"abstract_t\">1,3-5</a>]. Vomiting may be safely treated with an antiemetic (eg, <a href=\"topic.htm?path=ondansetron-drug-information\" class=\"drug drug_general\">ondansetron</a> 0.15 <span class=\"nowrap\">mg/kg</span> intravenously) and does not increase the amount of absorbed toxin. Antispasmodic agents (eg, <a href=\"topic.htm?path=loperamide-drug-information\" class=\"drug drug_general\">loperamide</a>) should be avoided in patients with diarrhea. Intravenous fluids should be given based upon clinical assessment of losses and evidence of dehydration. Patients with signs of shock should receive prompt fluid resuscitation (<a href=\"image.htm?imageKey=EM%2F77079\" class=\"graphic graphic_algorithm graphicRef77079 \">algorithm 1</a>). (See <a href=\"topic.htm?path=treatment-of-hypovolemia-or-hypovolemic-shock-in-adults\" class=\"medical medical_review\">&quot;Treatment of hypovolemia or hypovolemic shock in adults&quot;</a> and <a href=\"topic.htm?path=initial-management-of-shock-in-children\" class=\"medical medical_review\">&quot;Initial management of shock in children&quot;</a> and <a href=\"topic.htm?path=maintenance-and-replacement-fluid-therapy-in-adults\" class=\"medical medical_review\">&quot;Maintenance and replacement fluid therapy in adults&quot;</a> and <a href=\"topic.htm?path=treatment-of-hypovolemia-dehydration-in-children\" class=\"medical medical_review\">&quot;Treatment of hypovolemia (dehydration) in children&quot;</a>.)</p><p>If more serious mushroom poisoning cannot be excluded, patients should undergo initial baseline laboratory testing and be admitted for 24 to 48 hours to rule out progression to more serious conditions (eg, liver failure, renal failure). (See <a href=\"topic.htm?path=clinical-manifestations-and-evaluation-of-mushroom-poisoning#H21617150\" class=\"medical medical_review\">&quot;Clinical manifestations and evaluation of mushroom poisoning&quot;, section on 'Ancillary studies'</a> and <a href=\"topic.htm?path=clinical-manifestations-and-evaluation-of-mushroom-poisoning#H21621445\" class=\"medical medical_review\">&quot;Clinical manifestations and evaluation of mushroom poisoning&quot;, section on 'Delayed symptom onset (&gt;6 hours after ingestion)'</a> and <a href=\"#H1458107\" class=\"local\">'Disposition'</a> below.)</p><p class=\"headingAnchor\" id=\"H1129426\"><span class=\"h3\">Agitation, delirium, and/or hallucinations</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Central nervous system (CNS) excitation with hallucinations may occur after ingestion of mushrooms that contain psilocybin, psilocin, muscimol, or ibotenic acid [<a href=\"https://www.uptodate.com/contents/management-of-mushroom-poisoning/abstract/1,6-8\" class=\"abstract_t\">1,6-8</a>]. Patients with these findings should initially receive benzodiazepines (eg, <a href=\"topic.htm?path=midazolam-drug-information\" class=\"drug drug_general\">midazolam</a> 0.05 <span class=\"nowrap\">mg/kg,</span> typical maximum single dose 2 mg or <a href=\"topic.htm?path=lorazepam-drug-information\" class=\"drug drug_general\">lorazepam</a> 0.05 to 0.1 <span class=\"nowrap\">mg/kg,</span> typical maximum single dose 2 to 4 mg) and be placed in a quiet room. In some cases, physical restraints may also be necessary. <a href=\"topic.htm?path=physostigmine-drug-information\" class=\"drug drug_general\">Physostigmine</a> should be avoided since CNS excitation is not caused by anticholinergic effects. (See <a href=\"topic.htm?path=clinical-manifestations-and-evaluation-of-mushroom-poisoning#H21621724\" class=\"medical medical_review\">&quot;Clinical manifestations and evaluation of mushroom poisoning&quot;, section on 'Hallucinations'</a> and <a href=\"topic.htm?path=clinical-manifestations-and-evaluation-of-mushroom-poisoning#H21621879\" class=\"medical medical_review\">&quot;Clinical manifestations and evaluation of mushroom poisoning&quot;, section on 'CNS excitation and depression'</a> and <a href=\"topic.htm?path=intoxication-from-lsd-and-other-common-hallucinogens#H23\" class=\"medical medical_review\">&quot;Intoxication from LSD and other common hallucinogens&quot;, section on 'Agitation and dysphoria'</a>.)</p><p class=\"headingAnchor\" id=\"H1129433\"><span class=\"h3\">Seizures</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Seizures are associated with ingestion of mushrooms that contain gyromitrin, or in children, muscimol or ibotenic acid [<a href=\"https://www.uptodate.com/contents/management-of-mushroom-poisoning/abstract/9,10\" class=\"abstract_t\">9,10</a>]. Initial treatment includes oxygenation, support of airway and breathing, and administration of benzodiazepines (eg, <a href=\"topic.htm?path=lorazepam-drug-information\" class=\"drug drug_general\">lorazepam</a> 0.05 to 0.1 <span class=\"nowrap\">mg/kg,</span> typical maximum single dose 2 to 4 mg) (<a href=\"image.htm?imageKey=PEDS%2F55368\" class=\"graphic graphic_table graphicRef55368 \">table 2</a> and <a href=\"image.htm?imageKey=NEURO%2F74649\" class=\"graphic graphic_algorithm graphicRef74649 \">algorithm 2</a>). Pyridoxine (eg, 70 <span class=\"nowrap\">mg/kg</span> intravenously up to 5 g) should be given to patients with possible ingestion of gyromitrin-containing mushrooms and patients with unknown mushroom ingestion whose seizures are not controlled with standard anticonvulsant therapy [<a href=\"https://www.uptodate.com/contents/management-of-mushroom-poisoning/abstract/10\" class=\"abstract_t\">10</a>]. (See <a href=\"topic.htm?path=clinical-manifestations-and-evaluation-of-mushroom-poisoning#H21619997\" class=\"medical medical_review\">&quot;Clinical manifestations and evaluation of mushroom poisoning&quot;, section on 'Delayed gastroenteritis, seizures, and liver toxicity'</a> and <a href=\"topic.htm?path=clinical-manifestations-and-evaluation-of-mushroom-poisoning#H21621879\" class=\"medical medical_review\">&quot;Clinical manifestations and evaluation of mushroom poisoning&quot;, section on 'CNS excitation and depression'</a>.)</p><p class=\"headingAnchor\" id=\"H1129440\"><span class=\"h3\">Cholinergic excess</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Cholinergic symptoms include vomiting, diarrhea, salivation, bronchorrhea, bronchospasm, and bradycardia [<a href=\"https://www.uptodate.com/contents/management-of-mushroom-poisoning/abstract/11\" class=\"abstract_t\">11</a>]. Treatment consists of administration of anticholinergic medications until drying of respiratory secretions has occurred (eg, <a href=\"topic.htm?path=atropine-drug-information\" class=\"drug drug_general\">atropine</a> intravenously, 0.02 <span class=\"nowrap\">mg/kg</span> intravenously, minimum single dose: 0.1 mg, typical maximum single dose: 1 mg, or <a href=\"topic.htm?path=glycopyrrolate-glycopyrronium-drug-information\" class=\"drug drug_general\">glycopyrrolate</a> 10 <span class=\"nowrap\">mcg/kg</span> intravenously, typical maximum single dose: 0.2 mg). (See <a href=\"topic.htm?path=organophosphate-and-carbamate-poisoning#H12\" class=\"medical medical_review\">&quot;Organophosphate and carbamate poisoning&quot;, section on 'Atropine'</a>.) </p><p>Persistent vomiting may be treated with <a href=\"topic.htm?path=ondansetron-drug-information\" class=\"drug drug_general\">ondansetron</a> (eg, 0.1 <span class=\"nowrap\">mg/kg</span> intravenously, maximum typical single dose 4 mg).</p><p>Bronchospasm may be treated with inhaled <a href=\"topic.htm?path=albuterol-salbutamol-drug-information\" class=\"drug drug_general\">albuterol</a> combined with <a href=\"topic.htm?path=ipratropium-drug-information\" class=\"drug drug_general\">ipratropium</a> bromide using typical dosing for children (<a href=\"image.htm?imageKey=PEDS%2F53629\" class=\"graphic graphic_table graphicRef53629 \">table 3</a>) and adults (<a href=\"image.htm?imageKey=PULM%2F54125\" class=\"graphic graphic_table graphicRef54125 \">table 4</a>). Intravenous fluids should be given based upon clinical assessment of losses and evidence of dehydration. Patients with signs of shock should receive prompt fluid resuscitation (<a href=\"image.htm?imageKey=EM%2F77079\" class=\"graphic graphic_algorithm graphicRef77079 \">algorithm 1</a>). (See <a href=\"topic.htm?path=clinical-manifestations-and-evaluation-of-mushroom-poisoning#H21622033\" class=\"medical medical_review\">&quot;Clinical manifestations and evaluation of mushroom poisoning&quot;, section on 'Cholinergic poisoning'</a> and <a href=\"topic.htm?path=treatment-of-hypovolemia-or-hypovolemic-shock-in-adults\" class=\"medical medical_review\">&quot;Treatment of hypovolemia or hypovolemic shock in adults&quot;</a> and <a href=\"topic.htm?path=initial-management-of-shock-in-children\" class=\"medical medical_review\">&quot;Initial management of shock in children&quot;</a> and <a href=\"topic.htm?path=maintenance-and-replacement-fluid-therapy-in-adults\" class=\"medical medical_review\">&quot;Maintenance and replacement fluid therapy in adults&quot;</a> and <a href=\"topic.htm?path=treatment-of-hypovolemia-dehydration-in-children\" class=\"medical medical_review\">&quot;Treatment of hypovolemia (dehydration) in children&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H1129447\"><span class=\"h3\">Rhabdomyolysis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Patients with rhabdomyolysis typically present with the triad of pigmented granular casts in the urine, a red to brown color of the urine supernatant, and a marked elevation in the plasma level of creatine kinase (CK) one to three days after eating the mushroom <em>Tricholoma equestre</em> [<a href=\"https://www.uptodate.com/contents/management-of-mushroom-poisoning/abstract/12\" class=\"abstract_t\">12</a>]. (See <a href=\"topic.htm?path=clinical-manifestations-and-evaluation-of-mushroom-poisoning#H21620046\" class=\"medical medical_review\">&quot;Clinical manifestations and evaluation of mushroom poisoning&quot;, section on 'Delayed rhabdomyolysis'</a>.) </p><p>The primary treatment goals are similar to rhabdomyolysis from other causes and are discussed in detail elsewhere. (See <a href=\"topic.htm?path=prevention-and-treatment-of-heme-pigment-induced-acute-kidney-injury\" class=\"medical medical_review\">&quot;Prevention and treatment of heme pigment-induced acute kidney injury&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Fluid repletion with normal saline infusion (20 to 40 <span class=\"nowrap\">mL/kg</span> per hour up to 1 to 2 L per hour) &ndash; The emergency provider should closely monitor urine output with the goal of maintaining a minimum urine flow of 4 <span class=\"nowrap\">mL/kg</span> per hour; 200 mL per hour in adults. Alkalinization of the urine or the use of <a href=\"topic.htm?path=mannitol-drug-information\" class=\"drug drug_general\">mannitol</a> to increase diuresis may be associated with adverse effects and the efficacy of these strategies is uncertain. (See <a href=\"topic.htm?path=prevention-and-treatment-of-heme-pigment-induced-acute-kidney-injury#H25398992\" class=\"medical medical_review\">&quot;Prevention and treatment of heme pigment-induced acute kidney injury&quot;, section on 'Bicarbonate'</a> and <a href=\"topic.htm?path=prevention-and-treatment-of-heme-pigment-induced-acute-kidney-injury#H25398999\" class=\"medical medical_review\">&quot;Prevention and treatment of heme pigment-induced acute kidney injury&quot;, section on 'Mannitol'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Evaluation for significant electrolyte abnormalities (hyperkalemia, hyperphosphatemia, and hypocalcemia) &ndash; Management of hyperkalemia is of particular importance. Hypocalcemia is usually transient and calcium administration should be avoided unless severe symptoms (eg, tetany) are present. (See <a href=\"topic.htm?path=prevention-and-treatment-of-heme-pigment-induced-acute-kidney-injury#H25399014\" class=\"medical medical_review\">&quot;Prevention and treatment of heme pigment-induced acute kidney injury&quot;, section on 'Treatment of metabolic abnormalities'</a>.)</p><p/><p class=\"headingAnchor\" id=\"H1129454\"><span class=\"h3\">Liver failure</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Patients who have evidence of liver toxicity or who develop signs of mushroom poisoning more than six hours after ingestion have a high risk of developing acute liver failure caused by amatoxin- or gyromitrin-containing mushrooms. Managing patients with acute liver failure requires a thorough understanding of the many complications that can be present, including encephalopathy, cerebral edema, sepsis, renal failure, circulatory dysfunction, coagulopathy, gastrointestinal bleeding, and metabolic derangements such as metabolic acidosis, hypoglycemia, and hypophosphatemia. (See <a href=\"topic.htm?path=clinical-manifestations-and-evaluation-of-mushroom-poisoning#H21619990\" class=\"medical medical_review\">&quot;Clinical manifestations and evaluation of mushroom poisoning&quot;, section on 'Delayed gastroenteritis and liver toxicity'</a> and <a href=\"topic.htm?path=clinical-manifestations-and-evaluation-of-mushroom-poisoning#H21619997\" class=\"medical medical_review\">&quot;Clinical manifestations and evaluation of mushroom poisoning&quot;, section on 'Delayed gastroenteritis, seizures, and liver toxicity'</a> and <a href=\"topic.htm?path=amatoxin-containing-mushroom-poisoning-eg-amanita-phalloides-clinical-manifestations-diagnosis-and-treatment#H26667361\" class=\"medical medical_review\">&quot;Amatoxin-containing mushroom poisoning (eg, Amanita phalloides): Clinical manifestations, diagnosis, and treatment&quot;, section on 'Management'</a> and <a href=\"topic.htm?path=acute-liver-failure-in-adults-management-and-prognosis\" class=\"medical medical_review\">&quot;Acute liver failure in adults: Management and prognosis&quot;</a>.)</p><p>Because of the complexities involved, patients with acute liver failure should be managed in an intensive care unit in centers with an active liver transplant program. Patients admitted to hospitals without a transplant program should be transferred as soon as possible and ideally before the onset of the severe coagulopathy and increased intracranial pressure that may make later transfer dangerous. </p><p class=\"headingAnchor\" id=\"H1129461\"><span class=\"h3\">Renal failure</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Delayed renal insufficiency is associated with ingestion of mushrooms that contain orellanine or allenic norleucine [<a href=\"https://www.uptodate.com/contents/management-of-mushroom-poisoning/abstract/13,14\" class=\"abstract_t\">13,14</a>]. The major complications of renal failure include volume overload, hyperkalemia, metabolic acidosis, hypocalcemia, and hyperphosphatemia. The initial assessment therefore includes the careful evaluation of volume status and measurement of serum electrolytes, particularly potassium and bicarbonate, and evaluation of a complete blood count and serum phosphate, calcium, albumin and uric acid. (See <a href=\"topic.htm?path=clinical-manifestations-and-evaluation-of-mushroom-poisoning#H507571\" class=\"medical medical_review\">&quot;Clinical manifestations and evaluation of mushroom poisoning&quot;, section on 'Acute gastroenteritis and delayed renal failure'</a> and <a href=\"topic.htm?path=clinical-manifestations-and-evaluation-of-mushroom-poisoning#H21620032\" class=\"medical medical_review\">&quot;Clinical manifestations and evaluation of mushroom poisoning&quot;, section on 'Delayed renal failure'</a>.) </p><p>Accepted indications for dialysis in patients with renal failure generally include (see <a href=\"topic.htm?path=renal-replacement-therapy-dialysis-in-acute-kidney-injury-in-adults-indications-timing-and-dialysis-dose\" class=\"medical medical_review\">&quot;Renal replacement therapy (dialysis) in acute kidney injury in adults: Indications, timing, and dialysis dose&quot;</a>):</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Fluid overload that is refractory to diuretics</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Hyperkalemia (serum potassium concentration &gt;6.5 <span class=\"nowrap\">mEq/L)</span> or rapidly rising serum potassium, as can occur in rhabdomyolysis</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Metabolic acidosis (arterial pH less than 7.10) in patients with volume overload, which will be made worse by the administration of <a href=\"topic.htm?path=sodium-bicarbonate-drug-information\" class=\"drug drug_general\">sodium bicarbonate</a>, or with lactic acidosis, which is generally not treated with bicarbonate</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Signs of uremia, such as pericarditis, neuropathy, or an otherwise unexplained decline in mental status</p><p/><p class=\"headingAnchor\" id=\"H374522997\"><span class=\"h3\">Erythromelalgia</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Erythromelalgia is characterized by burning pain, swelling, and reddening or flushing in the extremities. Ingestion of Clitocybe species including <em>acromelalga</em> and <em>amoenolens</em> has been associated with the development of erythromelalgia. (See <a href=\"topic.htm?path=clinical-manifestations-and-evaluation-of-mushroom-poisoning#H21620067\" class=\"medical medical_review\">&quot;Clinical manifestations and evaluation of mushroom poisoning&quot;, section on 'Erythromelalgia'</a>.) </p><p>Treatment consists of supportive care (eg, elevation of the extremities to reduce edema) and pain control. One case of rapid improvement in pain and erythema after intravenous and oral nicotinic acid therapy has been described [<a href=\"https://www.uptodate.com/contents/management-of-mushroom-poisoning/abstract/15,16\" class=\"abstract_t\">15,16</a>]. </p><p class=\"headingAnchor\" id=\"H4264318813\"><span class=\"h2\">Shitake dermatitis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Dermatitis is characterized by pruritic, erythematous, flagellate eruptions on either the trunk or the extremities 2 hours to 5 days after ingestion of raw or undercooked shitake mushrooms (<em>Lentinula edodes</em>). (See <a href=\"topic.htm?path=clinical-manifestations-and-evaluation-of-mushroom-poisoning#H1975403867\" class=\"medical medical_review\">&quot;Clinical manifestations and evaluation of mushroom poisoning&quot;, section on 'Shiitake dermatitis'</a>.) </p><p>Treatment is supportive. Corticosteroids and antihistamines can be used in severe cases. </p><p class=\"headingAnchor\" id=\"H5135083\"><span class=\"h2\">Gastrointestinal decontamination</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>We recommend that patients who are alert and present for care within one hour of a potentially toxic mushroom ingestion receive activated charcoal (AC). The recommendation of AC administration following toxic mushroom exposure derives from indirect evidence of benefit in volunteers and in animal studies, as well as from evidence of benefit following ingestions of other medications. Mushrooms, like most complex xenobiotics, bind well to activated charcoal. Because of adverse effects, such as vomiting and volume depletion, the combination of a cathartic (eg, <a href=\"topic.htm?path=sorbitol-drug-information\" class=\"drug drug_general\">sorbitol</a>) and AC should be used sparingly, if at all, and only a single dose of a cathartic should ever be given to any patient. (See <a href=\"topic.htm?path=gastrointestinal-decontamination-of-the-poisoned-patient#H18993761\" class=\"medical medical_review\">&quot;Gastrointestinal decontamination of the poisoned patient&quot;, section on 'Activated charcoal'</a> and <a href=\"topic.htm?path=gastrointestinal-decontamination-of-the-poisoned-patient#H18993978\" class=\"medical medical_review\">&quot;Gastrointestinal decontamination of the poisoned patient&quot;, section on 'Cathartics'</a>.)</p><p>The greatest benefit occurs if AC is given within one hour. The efficacy of AC as a function of time from ingestion is discussed in detail separately. (See <a href=\"topic.htm?path=gastrointestinal-decontamination-of-the-poisoned-patient#H26755739\" class=\"medical medical_review\">&quot;Gastrointestinal decontamination of the poisoned patient&quot;, section on 'Evidence of efficacy and adverse effects'</a>.)</p><p><br/>We recommend that patients who ingest potentially toxic mushrooms <strong>not</strong> undergo gastric emptying by gastric lavage or syrup of ipecac in the emergency department. Syrup of ipecac administered in remote locations far from medical treatment soon after pediatric ingestion may prevent toxicity [<a href=\"https://www.uptodate.com/contents/management-of-mushroom-poisoning/abstract/9\" class=\"abstract_t\">9</a>]. Most serious mushroom poisonings are only detected hours after ingestion, and exploratory ingestions by children typically consist of small ingestions that rarely have serious consequences [<a href=\"https://www.uptodate.com/contents/management-of-mushroom-poisoning/abstract/9\" class=\"abstract_t\">9</a>]. Furthermore, randomized controlled trials show minimal benefit and possible risk to patients who undergo gastric emptying after poisoning. (See <a href=\"topic.htm?path=gastrointestinal-decontamination-of-the-poisoned-patient#H18993776\" class=\"medical medical_review\">&quot;Gastrointestinal decontamination of the poisoned patient&quot;, section on 'Indications'</a> and <a href=\"topic.htm?path=gastrointestinal-decontamination-of-the-poisoned-patient#H18993963\" class=\"medical medical_review\">&quot;Gastrointestinal decontamination of the poisoned patient&quot;, section on 'Syrup of Ipecac'</a>.)</p><p class=\"headingAnchor\" id=\"H1457959\"><span class=\"h2\">Elimination enhancement</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Multiple dose activated charcoal (MDAC) may decrease circulation of amatoxins after ingestion of amatoxin-containing mushrooms and is suggested to treat patients at risk for delayed hepatotoxicity. MDAC does not appear to improve poisoning outcomes after ingestion of mushrooms that contain toxins other than amatoxin. (See <a href=\"topic.htm?path=amatoxin-containing-mushroom-poisoning-eg-amanita-phalloides-clinical-manifestations-diagnosis-and-treatment#H26667361\" class=\"medical medical_review\">&quot;Amatoxin-containing mushroom poisoning (eg, Amanita phalloides): Clinical manifestations, diagnosis, and treatment&quot;, section on 'Management'</a>.)</p><p>Hemodialysis or hemoperfusion do <strong>not</strong> remove significant amounts of mushroom toxins.</p><p class=\"headingAnchor\" id=\"H1457979\"><span class=\"h2\">Antidotes</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>For most mushroom poisonings, supportive care is the main treatment. However, specific antidotes are available for some mushroom poisonings and may be helpful for patients with seizures and delayed gastroenteritis, methemoglobinemia, or cholinergic excess:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Patients who have ingested mushrooms that contain gyromitrin and who develop seizures should receive pyridoxine (70 <span class=\"nowrap\">mg/kg,</span> maximum dose: 5 g) in addition to standard anticonvulsant therapy (eg, <a href=\"topic.htm?path=lorazepam-drug-information\" class=\"drug drug_general\">lorazepam</a>) (<a href=\"image.htm?imageKey=NEURO%2F74649\" class=\"graphic graphic_algorithm graphicRef74649 \">algorithm 2</a>). This therapy reverses pyridoxal-5-phosphate deficiency in the CNS mediated by the toxic metabolite, monomethylhydrazine [<a href=\"https://www.uptodate.com/contents/management-of-mushroom-poisoning/abstract/3\" class=\"abstract_t\">3</a>]. (See <a href=\"#H1129433\" class=\"local\">'Seizures'</a> above and <a href=\"topic.htm?path=clinical-manifestations-and-evaluation-of-mushroom-poisoning#H21619997\" class=\"medical medical_review\">&quot;Clinical manifestations and evaluation of mushroom poisoning&quot;, section on 'Delayed gastroenteritis, seizures, and liver toxicity'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Patients who develop methemoglobinemia after consumption of mushrooms that contain gyromitrin may benefit from the administration of <a href=\"topic.htm?path=methylene-blue-drug-information\" class=\"drug drug_general\">methylene blue</a> (1 to 2 <span class=\"nowrap\">mg/kg</span> slowly infused over five minutes) if the methemoglobin level is above 20 percent or causing symptoms. (See <a href=\"topic.htm?path=clinical-features-diagnosis-and-treatment-of-methemoglobinemia#H21\" class=\"medical medical_review\">&quot;Clinical features, diagnosis, and treatment of methemoglobinemia&quot;, section on 'Treatment of hereditary methemoglobinemia'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Patients with evidence of cholinergic excess and respiratory distress should receive anticholinergic agents (eg, <a href=\"topic.htm?path=atropine-drug-information\" class=\"drug drug_general\">atropine</a> intravenously, 0.02 <span class=\"nowrap\">mg/kg</span> intravenously, minimum single dose: 0.1 mg, typical maximum single dose: 1 mg, or <a href=\"topic.htm?path=glycopyrrolate-glycopyrronium-drug-information\" class=\"drug drug_general\">glycopyrrolate</a> 10 <span class=\"nowrap\">mcg/kg</span> intravenously, typical maximum single dose: 0.2 mg). (See <a href=\"#H1129440\" class=\"local\">'Cholinergic excess'</a> above and <a href=\"topic.htm?path=clinical-manifestations-and-evaluation-of-mushroom-poisoning#H21622033\" class=\"medical medical_review\">&quot;Clinical manifestations and evaluation of mushroom poisoning&quot;, section on 'Cholinergic poisoning'</a> and <a href=\"topic.htm?path=organophosphate-and-carbamate-poisoning#H12\" class=\"medical medical_review\">&quot;Organophosphate and carbamate poisoning&quot;, section on 'Atropine'</a>.)</p><p/><p class=\"headingAnchor\" id=\"H1458107\"><span class=\"h2\">Disposition</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Consultation with a regional or international poison control center is advised to assist with disposition decisions. (See <a href=\"#H10901487\" class=\"local\">'Additional resources'</a> below.)</p><p>The following patients warrant hospital admission [<a href=\"https://www.uptodate.com/contents/management-of-mushroom-poisoning/abstract/1\" class=\"abstract_t\">1</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Patients with delayed symptoms more than six hours after mushroom ingestion</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Patients with early symptoms less than three hours after mushroom ingestion who remain symptomatic beyond six hours despite supportive care or who ingested more than one type of mushroom</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Patients with evidence of rhabdomyolysis, liver toxicity, or renal insufficiency </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Asymptomatic patients in whom ingestion of amatoxin-containing mushrooms is strongly suspected</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Asymptomatic patients in whom follow-up at 24 hours cannot be assured</p><p/><p>Asymptomatic patients in whom evaluation at 24 hours is assured may be discharged. Patients with early symptoms that resolve and in whom the ingestion of delayed toxicity mushrooms can be reliably excluded based upon history, clinical manifestations, and when possible, mushroom identification, may also be discharged with follow-up by phone or in person at 24 hours. </p><p class=\"headingAnchor\" id=\"H10901487\"><span class=\"h1\">ADDITIONAL RESOURCES</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Consultation with knowledgeable poison specialists, medical toxicologists, and mycologists is available through regional poison control centers. In the United States, call 1-800-222-1222 or access the World Health Organization's list of international poison centers (<a href=\"http://www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html&amp;token=vYXClxsD0hnrf4M8kYcoD1kMICrGjKQRRaFc8pA0pw9qlhpVmsmYh2e3Gi7webw9H9uSzH3nipQ0rPpTLYBWhGP+/wpQqUegRzvggwgKA6s=&amp;TOPIC_ID=13894\" target=\"_blank\" class=\"external\">www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html</a>).</p><p>The toxicology section of the North American Mycological Association (NAMA) website provides lists of emergency identification volunteers available in North America, an overview of mushroom poisoning syndromes with pictures, and archived toxicology reports that describe specifics of poisoning cases in which NAMA mycologists provided assistance (<a href=\"http://www.namyco.org/toxicology/index.html&amp;token=0kQT3eXJw+rNOP0+8f9imY8MsHKYSsPg3l0VNG7JkACRXuNZIQH7PMe70qXAN/KZRRVRNnBk0Vu0FBbFG6v8gQ==&amp;TOPIC_ID=13894\" target=\"_blank\" class=\"external\">www.namyco.org/toxicology/index.html</a>). </p><p class=\"headingAnchor\" id=\"H10901471\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Mushroom poisoning occurs frequently, but serious toxicity is uncommon. In most cases, the specific species of mushroom consumed is unknown. (See <a href=\"#H10900927\" class=\"local\">'Introduction'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Classification of poisoning based upon clinical presentation (<a href=\"image.htm?imageKey=EM%2F77875\" class=\"graphic graphic_table graphicRef77875 \">table 1</a>) is most helpful in guiding further treatment and more quickly arrives at the type of mushroom ingested in most instances. (See <a href=\"topic.htm?path=clinical-manifestations-and-evaluation-of-mushroom-poisoning#H21619983\" class=\"medical medical_review\">&quot;Clinical manifestations and evaluation of mushroom poisoning&quot;, section on 'Mushroom poisoning syndromes'</a> and <a href=\"topic.htm?path=clinical-manifestations-and-evaluation-of-mushroom-poisoning#H21617129\" class=\"medical medical_review\">&quot;Clinical manifestations and evaluation of mushroom poisoning&quot;, section on 'Evaluation'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A regional poison control center should be contacted to help determine likely mushroom species ingested based upon clinical findings, identification of any mushrooms available for analysis, and treatment of specific toxic effects. In the United States, call 1-800-222-1222 or access the World Health Organization's list of international poison centers (<a href=\"http://www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html&amp;token=vYXClxsD0hnrf4M8kYcoD1kMICrGjKQRRaFc8pA0pw9qlhpVmsmYh2e3Gi7webw9H9uSzH3nipQ0rPpTLYBWhGP+/wpQqUegRzvggwgKA6s=&amp;TOPIC_ID=13894\" target=\"_blank\" class=\"external\">www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html</a>). (See <a href=\"#H5135071\" class=\"local\">'General management'</a> above and <a href=\"#H10901487\" class=\"local\">'Additional resources'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>After careful assessment and support of airway, breathing, and circulation as needed, the clinician should anticipate and aggressively manage fluid losses caused by vomiting and diarrhea, which are common findings after toxic mushroom ingestion. The clinician should also be ready to treat toxicity caused by any of the potential mushroom syndromes (<a href=\"image.htm?imageKey=EM%2F77875\" class=\"graphic graphic_table graphicRef77875 \">table 1</a>). (See <a href=\"#H20098225\" class=\"local\">'Supportive care'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>We recommend that patients who are alert and present for care within one hour of a potentially toxic mushroom ingestion receive activated charcoal (<a href=\"grade.htm?i=2\" class=\"grade\">Grade 1B</a>). (See <a href=\"#H5135083\" class=\"local\">'Gastrointestinal decontamination'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>We recommend that patients who ingest potentially toxic mushrooms <strong>not</strong> undergo gastric emptying by gastric lavage or syrup of ipecac in the emergency department (<a href=\"grade.htm?i=2\" class=\"grade\">Grade 1B</a>). (See <a href=\"#H5135083\" class=\"local\">'Gastrointestinal decontamination'</a> above and <a href=\"topic.htm?path=clinical-manifestations-and-evaluation-of-mushroom-poisoning#H21617164\" class=\"medical medical_review\">&quot;Clinical manifestations and evaluation of mushroom poisoning&quot;, section on 'Mushroom identification'</a>.) </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The following patients warrant hospital admission (see <a href=\"#H1458107\" class=\"local\">'Disposition'</a> above):</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Patients with delayed symptoms more than six hours after mushroom ingestion</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Patients with early symptoms less than three hours after mushroom ingestion who remain symptomatic beyond six hours despite supportive care or who ingested more than one type of mushroom</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Patients with evidence of rhabdomyolysis, liver toxicity, or renal insufficiency </p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Asymptomatic patients in whom ingestion of amatoxin-containing mushrooms is strongly suspected</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Asymptomatic patients in whom follow-up at 24 hours cannot be assured</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The diagnosis and treatment of poisoning caused by amatoxin-containing mushrooms (eg, <em>Amanita phalloides</em>) or <em>Amanita smithiana</em> are discussed in greater detail separately. (See <a href=\"topic.htm?path=amatoxin-containing-mushroom-poisoning-eg-amanita-phalloides-clinical-manifestations-diagnosis-and-treatment\" class=\"medical medical_review\">&quot;Amatoxin-containing mushroom poisoning (eg, Amanita phalloides): Clinical manifestations, diagnosis, and treatment&quot;</a> and <a href=\"topic.htm?path=amanita-smithiana-mushroom-poisoning\" class=\"medical medical_review\">&quot;Amanita smithiana mushroom poisoning&quot;</a>.)</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li class=\"breakAll\">Goldfrank LR. Mushrooms. In: Goldfrank's Toxicologic Emergencies, 9th ed, Nelson LS, Lewin NA, Howland MA, et al. (Eds), McGraw-Hill, New York 2011. p.1522.</li><li><a href=\"https://www.uptodate.com/contents/management-of-mushroom-poisoning/abstract/2\" class=\"nounderline abstract_t\">Bronstein AC, Spyker DA, Cantilena LR Jr, et al. 2008 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 26th Annual Report. Clin Toxicol (Phila) 2009; 47:911.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-mushroom-poisoning/abstract/3\" class=\"nounderline abstract_t\">Berger KJ, Guss DA. Mycotoxins revisited: Part II. J Emerg Med 2005; 28:175.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-mushroom-poisoning/abstract/4\" class=\"nounderline abstract_t\">Berger KJ, Guss DA. Mycotoxins revisited: Part I. J Emerg Med 2005; 28:53.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-mushroom-poisoning/abstract/5\" class=\"nounderline abstract_t\">Diaz JH. Evolving global epidemiology, syndromic classification, general management, and prevention of unknown mushroom poisonings. Crit Care Med 2005; 33:419.</a></li><li class=\"breakAll\">Brent J, Palmer RB. Mushrooms. In: Haddad and Winchester's Clinical Management of Poisoning and Drug Overdose, 4th ed, Shannon MW, Borron SW, Burns MJ (Eds), Saunders Elsevier, Philadelphia, PA 2007. p.455.</li><li><a href=\"https://www.uptodate.com/contents/management-of-mushroom-poisoning/abstract/7\" class=\"nounderline abstract_t\">Benjamin DR. Mushroom poisoning in infants and children: the Amanita pantherina/muscaria group. J Toxicol Clin Toxicol 1992; 30:13.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-mushroom-poisoning/abstract/8\" class=\"nounderline abstract_t\">Satora L, Pach D, Butryn B, et al. Fly agaric (Amanita muscaria) poisoning, case report and review. Toxicon 2005; 45:941.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-mushroom-poisoning/abstract/9\" class=\"nounderline abstract_t\">Beuhler MC, Sasser HC, Watson WA. The outcome of North American pediatric unintentional mushroom ingestions with various decontamination treatments: an analysis of 14 years of TESS data. Toxicon 2009; 53:437.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-mushroom-poisoning/abstract/10\" class=\"nounderline abstract_t\">Michelot D, Toth B. Poisoning by Gyromitra esculenta--a review. J Appl Toxicol 1991; 11:235.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-mushroom-poisoning/abstract/11\" class=\"nounderline abstract_t\">Pauli JL, Foot CL. Fatal muscarinic syndrome after eating wild mushrooms. Med J Aust 2005; 182:294.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-mushroom-poisoning/abstract/12\" class=\"nounderline abstract_t\">Bedry R, Baudrimont I, Deffieux G, et al. Wild-mushroom intoxication as a cause of rhabdomyolysis. N Engl J Med 2001; 345:798.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-mushroom-poisoning/abstract/13\" class=\"nounderline abstract_t\">West PL, Lindgren J, Horowitz BZ. Amanita smithiana mushroom ingestion: a case of delayed renal failure and literature review. J Med Toxicol 2009; 5:32.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-mushroom-poisoning/abstract/14\" class=\"nounderline abstract_t\">Danel VC, Saviuc PF, Garon D. Main features of Cortinarius spp. poisoning: a literature review. Toxicon 2001; 39:1053.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-mushroom-poisoning/abstract/15\" class=\"nounderline abstract_t\">Nakajima N, Ueda M, Higashi N, Katayama Y. Erythromelalgia associated with Clitocybe acromelalga intoxication. Clin Toxicol (Phila) 2013; 51:451.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-mushroom-poisoning/abstract/16\" class=\"nounderline abstract_t\">Diaz JH. Syndromic diagnosis and management of confirmed mushroom poisonings. Crit Care Med 2005; 33:427.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 13894 Version 6.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H10901471\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H10900927\" id=\"outline-link-H10900927\">INTRODUCTION</a></li><li><a href=\"#H25646897\" id=\"outline-link-H25646897\">AMATOXIN-CONTAINING MUSHROOM POISONING</a></li><li><a href=\"#H5135071\" id=\"outline-link-H5135071\">GENERAL MANAGEMENT</a><ul><li><a href=\"#H20098225\" id=\"outline-link-H20098225\">Supportive care</a><ul><li><a href=\"#H1129419\" id=\"outline-link-H1129419\">- Vomiting and diarrhea</a></li><li><a href=\"#H1129426\" id=\"outline-link-H1129426\">- Agitation, delirium, and/or hallucinations</a></li><li><a href=\"#H1129433\" id=\"outline-link-H1129433\">- Seizures</a></li><li><a href=\"#H1129440\" id=\"outline-link-H1129440\">- Cholinergic excess</a></li><li><a href=\"#H1129447\" id=\"outline-link-H1129447\">- Rhabdomyolysis</a></li><li><a href=\"#H1129454\" id=\"outline-link-H1129454\">- Liver failure</a></li><li><a href=\"#H1129461\" id=\"outline-link-H1129461\">- Renal failure</a></li><li><a href=\"#H374522997\" id=\"outline-link-H374522997\">- Erythromelalgia</a></li></ul></li><li><a href=\"#H4264318813\" id=\"outline-link-H4264318813\">Shitake dermatitis</a></li><li><a href=\"#H5135083\" id=\"outline-link-H5135083\">Gastrointestinal decontamination</a></li><li><a href=\"#H1457959\" id=\"outline-link-H1457959\">Elimination enhancement</a></li><li><a href=\"#H1457979\" id=\"outline-link-H1457979\">Antidotes</a></li><li><a href=\"#H1458107\" id=\"outline-link-H1458107\">Disposition</a></li></ul></li><li><a href=\"#H10901487\" id=\"outline-link-H10901487\">ADDITIONAL RESOURCES</a></li><li><a href=\"#H10901471\" id=\"outline-link-H10901471\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"EM/13894|ALG\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"ALGORITHMS\">ALGORITHMS</a></div><ul><li><a href=\"image.htm?imageKey=EM/77079\" class=\"graphic graphic_algorithm\">- Initial management of undifferentiated shock in children </a></li><li><a href=\"image.htm?imageKey=NEURO/74649\" class=\"graphic graphic_algorithm\">- Treatment of convulsive status epilepticus in adults</a></li></ul></li><li><div id=\"EM/13894|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=EM/77875\" class=\"graphic graphic_table\">- Mushroom poisoning syndromes</a></li><li><a href=\"image.htm?imageKey=PEDS/55368\" class=\"graphic graphic_table\">- Management of status epilepticus in children</a></li><li><a href=\"image.htm?imageKey=PEDS/53629\" class=\"graphic graphic_table\">- Medication doses for pediatric acute asthma</a></li><li><a href=\"image.htm?imageKey=PULM/54125\" class=\"graphic graphic_table\">- Severe asthma exacerbation in adults rapid overview</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=acute-liver-failure-in-adults-management-and-prognosis\" class=\"medical medical_review\">Acute liver failure in adults: Management and prognosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=amanita-smithiana-mushroom-poisoning\" class=\"medical medical_review\">Amanita smithiana mushroom poisoning</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=amatoxin-containing-mushroom-poisoning-eg-amanita-phalloides-clinical-manifestations-diagnosis-and-treatment\" class=\"medical medical_review\">Amatoxin-containing mushroom poisoning (eg, Amanita phalloides): Clinical manifestations, diagnosis, and treatment</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-features-diagnosis-and-treatment-of-methemoglobinemia\" class=\"medical medical_review\">Clinical features, diagnosis, and treatment of methemoglobinemia</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-and-evaluation-of-mushroom-poisoning\" class=\"medical medical_review\">Clinical manifestations and evaluation of mushroom poisoning</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=gastrointestinal-decontamination-of-the-poisoned-patient\" class=\"medical medical_review\">Gastrointestinal decontamination of the poisoned patient</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=initial-management-of-shock-in-children\" class=\"medical medical_review\">Initial management of shock in children</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=intoxication-from-lsd-and-other-common-hallucinogens\" class=\"medical medical_review\">Intoxication from LSD and other common hallucinogens</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=maintenance-and-replacement-fluid-therapy-in-adults\" class=\"medical medical_review\">Maintenance and replacement fluid therapy in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=organophosphate-and-carbamate-poisoning\" class=\"medical medical_review\">Organophosphate and carbamate poisoning</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=prevention-and-treatment-of-heme-pigment-induced-acute-kidney-injury\" class=\"medical medical_review\">Prevention and treatment of heme pigment-induced acute kidney injury</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=renal-replacement-therapy-dialysis-in-acute-kidney-injury-in-adults-indications-timing-and-dialysis-dose\" class=\"medical medical_review\">Renal replacement therapy (dialysis) in acute kidney injury in adults: Indications, timing, and dialysis dose</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-hypovolemia-dehydration-in-children\" class=\"medical medical_review\">Treatment of hypovolemia (dehydration) in children</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-hypovolemia-or-hypovolemic-shock-in-adults\" class=\"medical medical_review\">Treatment of hypovolemia or hypovolemic shock in adults</a></li></ul></div></div>","javascript":null}